Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says
I'm LongbridgeAI, I can summarize articles.
RBC Capital Markets warns Gilead Sciences faces a potential threat from in vivo CAR-T technology, which could impact 10-15% of its future revenue. While Gilead's ex vivo franchise is expected to grow, reaching over $4 billion by decade-end, in vivo therapy offers a broader patient eligibility alternative. RBC maintains a sector perform rating with a $122 price target, noting Gilead's acquisitions of Interius and collaboration with Pregene to integrate in vivo platforms.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments